9 wk, Randomized, 2-blind, Placebo-controlled, 2X2 Cross-over Phase 1 Study of 25 mg of Scelectium Tortuosum (as Zembrin) in Aged Normals to Find Effects on Mental, Emotional and Cognitive Safety Measures and Cytokines.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Scelectium tortuosum (Primary)
- Indications Cognition disorders; Neurodegenerative disorders
- Focus Adverse reactions; Biomarker
- 15 Mar 2013 New trial record
- 06 Mar 2013 Biomarkers information updated